The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

EGR3  -  early growth response 3

Homo sapiens

Synonyms: EGR-3, Early growth response protein 3, PILOT, Zinc finger protein pilot
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EGR3


Psychiatry related information on EGR3


High impact information on EGR3

  • Egr3 was highly expressed in developing muscle spindles, but not in Ia afferent neurons or their terminals during developmental periods that coincided with the induction of spindle morphogenesis by sensory afferent axons [4].
  • These results indicate that type I myotubes are dependent upon Egr3-mediated transcription for proper spindle development [4].
  • BACKGROUND: Pilot studies indicate that probe-guided resection of radioactive sentinel nodes (the first nodes that receive drainage from tumors) can identify regional metastases in patients with breast cancer [11].
  • CONCLUSIONS: Progress toward reduction of youth tobacco use was observed in each of the 2 years of Florida's Pilot Program on Tobacco Control. Our results suggest that a comprehensive statewide program can be effective in preventing and reducing youth tobacco use [12].
  • The induction of monocytic differentiation by TPA and other agents was further associated with increases in EGR-2, but not EGR-3 or EGR-4, mRNA levels in these cells [13].

Chemical compound and disease context of EGR3


Biological context of EGR3


Anatomical context of EGR3

  • We show that EGR3 is an immediate-early growth response gene induced by mitogenic stimulation of rodent and human fibroblasts and a monkey kidney epithelial cell line [18].
  • Furthermore, a reporter assay using the upstream region of fasL probably involving escape from the immune system revealed that fasL is another target gene for EGR3 [2].
  • Previous literature indicates that Egr3 expression is required for the formation of muscle spindle fibers, sensory organs that are distinct from skeletal muscle contractile fibers [21].
  • To investigate this issue, we performed a detailed comparative analysis of the promoter regulating the two-signal-dependent (Ca2+ ionophore plus phorbol myristate acetate [PMA]), CsA-sensitive expression of EGR3 in T cells and the one-signal-dependent (PMA), CsA-insensitive expression of EGR3 in fibroblasts [19].
  • Northern analysis corroborated the lack of Egr3 in Th1 cells [22].

Associations of EGR3 with chemical compounds


Regulatory relationships of EGR3

  • Conversely, beta2- and PAF-mediated EGR-3 activation was blocked by the p38, specific inhibitor SB580 [25].

Other interactions of EGR3

  • Using stable transformants derived from MCF-7 cells which were transfected with expression-controllable Egr3-expression vector, we demonstrated that Nab2 is one of the target genes for EGR3 [2].
  • Western blots and electromobility shift assays demonstrated synthesis of EGR-1 and EGR-3, as well as binding to DNA recognition sites in response to m1AChR activation [26].
  • As a result, we identified a 27-bp promoter element functionally interacting with transcription factors NF-ATp and NF-ATc that is crucial for the CsA-sensitive expression of the EGR3 gene in T cells [19].
  • Our data also indicate that 15d-PGJ(2) represses rankl activation by interfering with the expression and/or activity of the transcription factors NF-kappaB, early growth response-2, and early growth response-3, whose altered balancing and transactivation may contribute for the repression of this gene [27].
  • Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany [28].

Analytical, diagnostic and therapeutic context of EGR3


  1. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Yasunaga, J., Taniguchi, Y., Nosaka, K., Yoshida, M., Satou, Y., Sakai, T., Mitsuya, H., Matsuoka, M. Cancer Res. (2004) [Pubmed]
  2. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. Inoue, A., Omoto, Y., Yamaguchi, Y., Kiyama, R., Hayashi, S.I. J. Mol. Endocrinol. (2004) [Pubmed]
  3. Brain-derived Neurotrophic Factor (BDNF)-induced Synthesis of Early Growth Response Factor 3 (Egr3) Controls the Levels of Type A GABA Receptor{alpha}4 Subunits in Hippocampal Neurons. Roberts, D.S., Hu, Y., Lund, I.V., Brooks-Kayal, A.R., Russek, S.J. J. Biol. Chem. (2006) [Pubmed]
  4. Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3. Tourtellotte, W.G., Milbrandt, J. Nat. Genet. (1998) [Pubmed]
  5. Evidence of cadmium toxicity in a population living in a zinc-mining area. Pilot survey of Shipham residents. Carruthers, M., Smith, B. Lancet (1979) [Pubmed]
  6. The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Cassano, G.B., Michelini, S., Shear, M.K., Coli, E., Maser, J.D., Frank, E. The American journal of psychiatry. (1997) [Pubmed]
  7. The positive triad of schizophrenic symptoms. Its statistical properties and its relationship to 13 traditional diagnostic systems. Landmark, J., Merskey, H., Cernovsky, Z., Helmes, E. The British journal of psychiatry : the journal of mental science. (1990) [Pubmed]
  8. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. Riggs, P.D., Leon, S.L., Mikulich, S.K., Pottle, L.C. Journal of the American Academy of Child and Adolescent Psychiatry. (1998) [Pubmed]
  9. Schizophrenia succeeded by affective illness; catamnestic study and statistical enquiry. Sheldrick, C., Jablensky, A., Sartorius, N., Shepherd, M. Psychological medicine. (1977) [Pubmed]
  10. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. Riggs, P.D., Thompson, L.L., Mikulich, S.K., Whitmore, E.A., Crowley, T.J. Journal of the American Academy of Child and Adolescent Psychiatry. (1996) [Pubmed]
  11. The sentinel node in breast cancer--a multicenter validation study. Krag, D., Weaver, D., Ashikaga, T., Moffat, F., Klimberg, V.S., Shriver, C., Feldman, S., Kusminsky, R., Gadd, M., Kuhn, J., Harlow, S., Beitsch, P. N. Engl. J. Med. (1998) [Pubmed]
  12. Changes in youth cigarette use and intentions following implementation of a tobacco control program: findings from the Florida Youth Tobacco Survey, 1998-2000. Bauer, U.E., Johnson, T.M., Hopkins, R.S., Brooks, R.G. JAMA (2000) [Pubmed]
  13. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. Kharbanda, S., Nakamura, T., Stone, R., Hass, R., Bernstein, S., Datta, R., Sukhatme, V.P., Kufe, D. J. Clin. Invest. (1991) [Pubmed]
  14. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Reichard, O., Norkrans, G., Frydén, A., Braconier, J.H., Sönnerborg, A., Weiland, O. Lancet (1998) [Pubmed]
  15. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Kedar, R.P., Bourne, T.H., Powles, T.J., Collins, W.P., Ashley, S.E., Cosgrove, D.O., Campbell, S. Lancet (1994) [Pubmed]
  16. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Cairns, J.A., Connolly, S.J., Gent, M., Roberts, R. Circulation (1991) [Pubmed]
  17. Dobutamine stress echocardiography in women with chest pain. Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Lewis, J.F., Lin, L., McGorray, S., Pepine, C.J., Doyle, M., Edmundowicz, D., Holubkov, R., Pohost, G., Reichek, N., Rogers, W., Sharaf, B.L., Sopko, G., Merz, C.N. J. Am. Coll. Cardiol. (1999) [Pubmed]
  18. EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. Patwardhan, S., Gashler, A., Siegel, M.G., Chang, L.C., Joseph, L.J., Shows, T.B., Le Beau, M.M., Sukhatme, V.P. Oncogene (1991) [Pubmed]
  19. Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a molecular model for the lymphoid cell-specific effect of cyclosporin A. Mages, H.W., Baag, R., Steiner, B., Kroczek, R.A. Mol. Cell. Biol. (1998) [Pubmed]
  20. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Jiang, Y.M., Yamamoto, M., Kobayashi, Y., Yoshihara, T., Liang, Y., Terao, S., Takeuchi, H., Ishigaki, S., Katsuno, M., Adachi, H., Niwa, J., Tanaka, F., Doyu, M., Yoshida, M., Hashizume, Y., Sobue, G. Ann. Neurol. (2005) [Pubmed]
  21. Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle. Jacobson, C., Duggan, D., Fischbach, G. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  22. Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. Dzialo-Hatton, R., Milbrandt, J., Hockett, R.D., Weaver, C.T. J. Immunol. (2001) [Pubmed]
  23. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Gurfinkel, E., Bozovich, G., Daroca, A., Beck, E., Mautner, B. Lancet (1997) [Pubmed]
  24. Could institutional clinical trials exist in Europe? EUTERP Pilot Study Group. European Trial of Estrogen/progestin Replacement treatment in Post-menopause. Cornu, C., Cano, A., Pornel, B., Melis, G.B., Boissel, J.P. Lancet (1999) [Pubmed]
  25. Integration of G-protein coupled receptor signaling pathways for activation of a transcription factor (EGR-3). Tan, X., Sanders, P., Bolado, J., Whitney, M. Genomics Proteomics Bioinformatics (2003) [Pubmed]
  26. Muscarinic acetylcholine receptors activate expression of the EGR gene family of transcription factors. von der Kammer, H., Mayhaus, M., Albrecht, C., Enderich, J., Wegner, M., Nitsch, R.M. J. Biol. Chem. (1998) [Pubmed]
  27. 15-Deoxy-{Delta}12,14-Prostaglandin J2 Negatively Regulates rankl Gene Expression in Activated T Lymphocytes: Role of NF-{kappa}B and Early Growth Response Transcription Factors. Fionda, C., Nappi, F., Piccoli, M., Frati, L., Santoni, A., Cippitelli, M. J. Immunol. (2007) [Pubmed]
  28. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany. Audebert, H.J., Kukla, C., Vatankhah, B., Gotzler, B., Schenkel, J., Hofer, S., Fürst, A., Haberl, R.L. Stroke (2006) [Pubmed]
  29. High-resolution, real-time ultrasonography in the preoperative location of parathyroid tumors. Pilot study. Edis, A.J., Evans, T.C. N. Engl. J. Med. (1979) [Pubmed]
  30. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography. Klein, A.L., Grimm, R.A., Black, I.W., Leung, D.Y., Chung, M.K., Vaughn, S.E., Murray, R.D., Miller, D.P., Arheart, K.L. Ann. Intern. Med. (1997) [Pubmed]
  31. Improved procedural results of coronary angioplasty with intravascular ultrasound-guided balloon sizing: the CLOUT Pilot Trial. Clinical Outcomes With Ultrasound Trial (CLOUT) Investigators. Stone, G.W., Hodgson, J.M., St Goar, F.G., Frey, A., Mudra, H., Sheehan, H., Linnemeier, T.J. Circulation (1997) [Pubmed]
  32. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Serruys, P.W., Emanuelsson, H., van der Giessen, W., Lunn, A.C., Kiemeney, F., Macaya, C., Rutsch, W., Heyndrickx, G., Suryapranata, H., Legrand, V., Goy, J.J., Materne, P., Bonnier, H., Morice, M.C., Fajadet, J., Belardi, J., Colombo, A., Garcia, E., Ruygrok, P., de Jaegere, P., Morel, M.A. Circulation (1996) [Pubmed]
WikiGenes - Universities